This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pacific Biosciences Releases Software To Detect DNA Base Modifications Using The PacBio® RS

Pacific Biosciences of California, Inc., (NASDAQ:PACB) today launched a new and unique solution to detect DNA base modifications associated with epigenetic regulation and DNA damage using the PacBio ® RS High Resolution Genetic Analyzer.

DNA base modifications such as methylation have an important role in a wide variety of biological processes such as growth and aging, immunity, bacterial pathogenicity, and disease development. The new analysis software for the PacBio ® RS enables customers to detect and visualize these DNA modifications. The software works by measuring the rate of DNA base incorporation during sequencing. This information, automatically gathered during the sequence process, is a unique feature of the company’s single molecule, real-time (SMRT ®) technology.

“We are pleased to provide the first and only tool that offers researchers worldwide the ability to detect base modifications as an integral part of the sequencing workflow,” said Kevin Corcoran, Senior Vice President of Market Development at Pacific Biosciences. “This is a major milestone for Pacific Biosciences and a valuable new tool for the scientific community.”

The SMRT Analysis software upgrade is available to scientists through a free download from PacBio’s DevNet portal. The analysis tool works on any data generated by the PacBio RS with its latest C2 chemistry, enabling researchers to re-analyze existing data to detect methylation and other base modifications.

More than 20 biologically important DNA base modifications are known, and new types continue to be discovered. The initial software release simplifies the process of detecting these modification events in native genomic DNA through a user-friendly analysis and visualization interface. Guidelines on studying the methylomes of bacteria, including N6-methyladenine and N4-methylcytosine, are also available on the company’s website at www.pacb.com/basemod.

“Modifications such as methylation have been shown to be critical in influencing disease onset and severity, the pathogenicity of bacteria, and gene regulation,” said Eric Schadt, Ph.D., Director of the Institute for Genomics and Multiscale Biology at Mt. Sinai Hospital and Chief Science Officer at Pacific Biosciences. “The work we have done using SMRT sequencing to resolve the German E. coli outbreak strain, for example, points to a crucial role for base modification in the regulation of a gene associated with the strain’s severity. If we aren’t looking at base modifications, we aren’t seeing the whole picture in the biology of pathogens.”

Dr. Schadt is speaking today about his work using the SMRT technology during the President’s Forum at the annual American Society for Microbiology’s 112 th General Meeting in San Francisco. The talk is entitled, “Whole-genome Characterization of Methyladenine Residues in Highly Pathogenic Strains of E. coli and V. cholerae and Their Impact on Function.”

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers the PacBio ® RS, a high resolution genetic analyzer, to help scientists solve genetically complex problems. Based on its novel single molecule, real-time (SMRT ®) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to genetic information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements may contain words such as "believe," "may," "estimate," "anticipate," "continue," "intend," "expect," "plan," the negative of these terms, or other similar expressions, and include the assumptions that underlie such statements. Such statements include, but are not limited to, statements regarding the Company’s SMRT technology. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to risks discussed from time to time in documents Pacific Biosciences of California, Inc. has filed with the Securities and Exchange Commission, including the risks identified under the section captioned "Risk Factors" in its recently filed Quarterly Report on Form 10-Q. All forward-looking statements are based on estimates, projections and assumptions as of the date hereof. Pacific Biosciences undertakes no obligation to update any forward-looking statements.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs